Adagio Medical Holdings, Inc. (ADGM): Results of Operations and Financial Condition
Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622801d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for th
How this was made
The 30-second read
Why it matters
Traders can use the filing to update near-term expectations for FDA review momentum (PMA submission supported by FULCRUM-VT IDE trial) while also reassessing liquidity and burn rate based on Q2 results.
Market read
The combination of Q2 financials and newly disclosed FDA-facing milestones (PMA submission support, first vCLAS Ultra patient) is likely to drive ADGM-specific sentiment and positioning.
What to watch
Cash and cash equivalents are only $7.7M as of June 30, 2026, and cost of revenue is nil due to a Europe commercial activity pause, both of which can dominate near-term valuation and financing expectations.
Background
This SEC 8-K (Item 2.02) reports Adagio’s Q2 2026 financials and highlights clinical/regulatory progress for its vCLAS ventricular ablation platform and next-generation vCLAS Ultra catheter.
Ticker impact
Adagio filed an 8-K with Q2 2026 results plus clinical and regulatory updates, including FULCRUM-VT data and a vCLAS PMA submission to the FDA.
Moderate upside bias on any market optimism around PMA progress, offset by cash burn and continued pre-revenue status.
The article discloses new operational milestones (first vCLAS Ultra patient under FDA expanded access, FULCRUM-VT pivotal IDE support for PMA) alongside Q2 financial deterioration (higher R&D, larger net loss, $7.7M cash). That mix typically supports biotech-style momentum but keeps downside risk from liquidity.
Market effects
Reinforces investor focus on FDA PMA pathways and ULTA/cryoblation differentiation in cardiac arrhythmia devices.
Europe commercial activity pause is cited as a driver of lower cost of revenue, highlighting regional execution risk.
Could marginally affect sentiment toward cardiac ablation device peers if PMA progress is viewed as de-risking the modality.
Counterpoint
Despite the PMA submission and positive trial metrics, the company remains pre-revenue in the US and reports a widening net loss with limited cash, so the market may discount clinical optimism.
Key entities
- companyAdagio Medical Holdings, Inc.
Nasdaq-listed medical device company reporting Q2 2026 results and FDA-related milestones for its vCLAS/ULTA catheter ablation technology.
- productvCLAS Ventricular Ablation System
CE Marked ventricular ablation system; Adagio submitted a PMA application to the FDA supported by FULCRUM-VT.
- productvCLAS Ultra Ultra-Low temperature ablation catheter (ULTA)
Next-generation catheter; first patient treated under FDA expanded access and evaluated under expanded IDE.
- clinical_trialFULCRUM-VT trial
209-patient pivotal IDE trial; late-breaking HRS 2026 presentation with reported safety and 6-month effectiveness metrics.
- regulatorU.S. Food and Drug Administration (FDA)
Granted IDE expansion and expanded access authorization referenced in the filing, supporting the PMA pathway.
